Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II molar extraction study evaluating otenaproxesul for post-operative pain

Next Previous
Trial Profile

Phase II molar extraction study evaluating otenaproxesul for post-operative pain

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Otenaproxesul (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Antibe Therapeutics

Most Recent Events

  • 12 Oct 2022 Status changed from planning to withdrawn prior to enrolment as the company wants to save resources and streamline the clinical path by bypassing this Phase II molar extraction study originally planned for the fall. Instead, the company capture the necessary data via a set of lower cost, de-risking animal studies, followed by an enhanced Phase II bunionectomy study to begin in the first half of next year as planned
  • 15 Aug 2022 According to an Antibe Therapeutics media release, the company expect to initiate this trial in September (Q3 2022) with results expected by January 2023 (early calendar Q1 2023).
  • 15 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top